Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.01 0.25 (2.13%) Market Cap: 527.03 Mil Enterprise Value: 442.37 Mil PE Ratio: 0 PB Ratio: 5.31 GF Score: 56/100

Y-mAbs Therapeutics, Inc. - Special Call Transcript

Dec 16, 2020 / 05:00PM GMT
Release Date Price: $52.67 (-2.25%)
Sara Parigian
LifeSci Advisors, LLC - VP of KOL Strategy & Management

(technical difficulty) strategy of Y-mAbs Therapeutics.

Thomas Gad
Y-mAbs Therapeutics, Inc. - Founder, Chairman, President & Head of Business Development and Strategy

Thank you, Sara. Good morning, and welcome to Y-mAbs R&D Day. Unfortunately, it's virtual today, but we are very happy to have it done today.

Let me quickly remind you that the following discussions contain certain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, and the disclaimer is on the screen right now. I'll give you a second.

Okay. So to the big news, the BLA for DANYELZA was approved November 25, and which was a fantastic milestone for Y-mAbs. This -- the first trial was started way back in 2003, so it's a big milestone. And today, we'll learn more about the very encouraging data that -- from the use of DANYELZA in clinic. First, we are pleased to have Dr. Shakeel Modak from the Memorial Sloan Kettering Cancer Center, talk about our HITS

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot